In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.News: COVID antibody treatments show promise for preventing severe diseaseNews: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.